Table 2.
Susceptibility Results Involving Pseudomonas aeruginosa and Acinetobacter baumannii from the 2017 Surveillance Collection and the 2013–2014 Carbapenem-Resistant Collection of Isolates
| MIC50 |
MIC90 |
Range |
|
|
|---|---|---|---|---|
| mg/L | Susceptible, % | |||
| 2017 surveillance isolates | ||||
| P. aeruginosa (n = 269) | ||||
| Cefiderocol | 0.25 | 0.5 | ≤0.03 to 8 | 99.6 |
| Piperacillin/tazobactam | 8/4 | 128/4 | 2/4 to >128/4 | 75 |
| Ceftazidime | 4 | 32 | 1 to >32 | 83 |
| Meropenem | 1 | 8 | ≤0.12 to >8 | 76 |
| Gentamicin | 2 | 8 | 0.5 to >16 | 79 |
| Ciprofloxacin | 0.25 | >4 | ≤0.12 to >4 | 69 |
| 2013–2014 Carbapenem-resistant surveillance isolates | ||||
| P. aeruginosa (n = 130) | ||||
| Cefiderocol | 0.5 | 1 | ≤0.03 to 4 | 100 |
| 2017 surveillance isolates | ||||
| A. baumannii (n = 46) | ||||
| Cefiderocol | 0.25 | 1 | 0.06 to 4 | 100 |
| Piperacillin/tazobactam | 32/4 | >128/4 | ≤0.25/4 to >128/4 | 43 |
| Ceftazidime | 8 | >32 | ≤0.12 to >32 | 54 |
| Meropenem | 4 | 8 | ≤0.12 to >8 | 48 |
| Gentamicin | 2 | >16 | 0.5 to >16 | 70 |
| Ciprofloxacin | >4 | >4 | ≤0.12 to >4 | 46 |
| 2013–2014 Carbapenem-resistant surveillance isolates | ||||
| A. baumannii (n = 78) | ||||
| Cefiderocol | 0.5 | 8 | 0.12 to >32 | 88 |